Российский кардиологический журнал (Oct 2003)
THE PROPANORM EFFICACY IN RAPID RELIEF OF SYMPTOMS OF PAROXYSMAL AURICULAR FIBRILLATION
Abstract
In aim to study efficacy and safety of propafenone (Propanorm), open prospective поп randomized study in-patients with paroxysmal form of auricular fibrillation (AF) was carried out. 31 patients - 16 men (51,6 % ) and 15 women (48,4 % ) with mean age 58, 1± 8 years were included in the study. The paroxysmal form AF was observed in 29 patients (93,5 % ), persistent form - in 2 patients (6,5 % ). The reason of arrhythmia in 21 patients (67,7 % ) was ischemic heart disease, in 12 patients (38,7 % >) - arterial hypertension, in 2 patients (6,4 % ) - rheumatic heart diseases, in 1 patient (3,2 % ) - idiopathic AF. The medication for rapid relief of symptoms of paroxysmal auricular fibrillation was administered in single stress dose 600 mg per os. Propanorm restored the rhythm in 74,2 % > patients. The disorder of intraventricular conduction on EKG became evi-dentin 7 patients (22,5 % ) in time from 2to 16. 5 hours (on average 5, 1 hour), atrioventricular heart block of I stage - in 2 patients (6,45 % ), aberrant ventricular complex - in 2 patients (6,45 % ), pacemaker migration and sinus bradycardia - in 1 patient (3,2 % ). This disorders eliminated independently without special intervention. Extracardiac side effects during single intake were not observed. Propafenone appeared to be high-performed antiarrhythmic medication in rapid relief of symptoms of paroxysmal auricular fibrillation. Its application is possible in the outpatient setting.